Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 6;7(12):e08556.
doi: 10.1016/j.heliyon.2021.e08556. eCollection 2021 Dec.

The effect of treatment with fexofenadine and fluticasone propionate on the gene expression levels of Th9 transcription factors in patients with allergic rhinitis

Ali Asghar Askari  1   2 , Parisa Feizollahi  2 , Alireza Rezaiemanesh  2 , Farhad Salari  2 , Ali Gorgin Karaji  2
Affiliations

The effect of treatment with fexofenadine and fluticasone propionate on the gene expression levels of Th9 transcription factors in patients with allergic rhinitis

Ali Asghar Askari et al. Heliyon. .

Abstract

T helper-9 (Th9) is a new T cell subset involved in allergic rhinitis (AR) pathogenesis. Fexofenadine and fluticasone propionate are the first effective line of AR treatment. This study aimed to evaluate the effect of fexofenadine and fluticasone propionate on the gene expression levels of Interferon regulatory factor 4 (IRF4), B cell-activating transcription factor-like (BATF), and SPI1 gene-encoded protein (PU.1), essential transcription factors for Th9 cell differentiation, in AR patients. Twenty-six AR patients (aged 32.8 ± 9.1 years, 13 men and 13 women) were treated with fexofenadine and fluticasone propionate for one month. Expression levels of PU.1, IRF4, and BATF genes were measured using Real-Time PCR. Our results showed that after one month of treatment, the expression level of IRF4 and BATF genes decreased significantly (P < 0.001, P < 0.01, respectively), while PU.1 gene expression was not remarkably different. Overall, our results showed that after one month of treatment with fexofenadine and fluticasone propionate, the expression levels of IRF4 and BATF genes in AR patients decreased, which may be due to this treatment regimen. However, the exact mechanism of action of fexofenadine and fluticasone propionate needs further study.

Keywords: Allergic rhinitis; BATF; Fexofenadine; Fluticasone propionate; IRF4; PU.1.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The effect of one month of treatment with fexofenadine and fluticasone propionate on the expression level of IRF4 and BATF genes. The expression levels of IRF4 and BATF genes were measured before and after one month of treatment with fluticasone propionate and fexofenadine by Real Time-PCR. The expression level of BATF (A) and IRF4 (B) transcription factors significantly decreased after one month of treatment compared to before treatment. (∗∗: P < 0.01, ∗∗∗: P < 0.001, respectively).
Figure 2
Figure 2
The effect of treatment with fexofenadine and fluticasone propionate on the gene expression level of PU.1 in AR patients. The expression levels of PU.1 gene was measured before and after one month of treatment with fexofenadine and fluticasone propionate by Real Time-PCR. No significant difference was found for the gene expression of PU.1 before and after one month of treatment. Ns: no significant.
See this image and copyright information in PMC

References

    1. Bousquet J., Khaltaev N., Cruz A., Denburg J., Fokkens W., Togias A., et al. LEN and AllerGen; 2008. World Health Organization; GA (2) LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update. (in collaboration with the world health organization, GA (2) - PubMed
    1. Eiwegger T., Soyka M.B. 2020. Allergic Rhinitis. Pediatric Allergy, E-Book: Principles and Practice; p. 135.
    1. Veldhoen M., Uyttenhove C., Van Snick J., Helmby H., Westendorf A., Buer J., et al. Transforming growth factor-β'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset. Nat. Immunol. 2008;9(12):1341–1346. - PubMed
    1. Pilette C., Jacobson M., Ratajczak C., Detry B., Banfield G., VanSnick J., et al. Aberrant dendritic cell function conditions Th2-cell polarization in allergic rhinitis. Allergy. 2013;68(3):312–321. - PubMed
    1. Ciprandi G., De Amici M., Murdaca G., Fenoglio D., Ricciardolo F., Marseglia G., et al. Serum interleukin-17 levels are related to clinical severity in allergic rhinitis. Allergy. 2009;64(9):1375–1378. - PubMed